IP Library Granted Patent US 12,251,152
Granted Patent B2
US 12,251,152 · App. 17/299,578 · Granted Mar 18, 2025

Ceramic applicator for transcutaneous delivery of energy

Inventors: Frederick Jay Bennett (Bellevue, WA); Craig Robert Bockenstedt (Bothell, WA)
Assignee: Solta Medical Ireland Limited
A61B18/14A61B2018/00095A61B2018/0047A61B18/1206A61B2018/142
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,251,152
App. No.
17/299,578
Granted
Mar 18, 2025
Kind
B2
Abstract

Structures for a bidirectional switch and methods of forming such structures. A substrate contact is formed in a trench defined in a substrate. A substrate includes a trench and a substrate contact in the trench. A bidirectional switch, which is on the substrate, includes a first source/drain electrode, a second source/drain electrode, an extension region between the first source/drain electrode and the second source/drain electrode, and a gate structure. A substrate-bias switch, which is on the substrate, includes a gate structure, a first source/drain electrode coupled to the substrate contact, a second source/drain electrode coupled to the first source/drain electrode of the bidirectional switch, and an extension region laterally between the gate structure and the first source/drain electrode.

Claims (38)

1. An energy delivery device comprising:

an applicator including an electrode and a substrate comprising a ceramic material, the substrate having a first surface, a second surface opposite to the first surface, and one or more outer edges between the first surface and the second surface, and the substrate having a thickness between the first surface and the second surface that varies as a function of position relative to the one or more outer edges,

wherein the ceramic material is aluminum nitride having a dielectric constant of about 9 in a frequency range from 1 Megahertz to 20 Megahertz, the substrate has a centerline, the ceramic material of the substrate extends from the centerline to the one or more outer edges, and the thickness of the ceramic material of the substrate increases non-linearly with increasing distance from the centerline.

2. The energy delivery device of claim 1 wherein the first surface of the substrate has a concave shape with a radius of curvature.

3. The energy delivery device of claim 2 wherein the second surface of the substrate is planar.

4. The energy delivery device of claim 3 wherein the electrode is arranged on the second surface of the substrate.

5. The energy delivery device of claim 2 wherein the electrode is arranged on the first surface of the substrate.

6. The energy delivery device of claim 1 wherein the electrode is centered about the centerline of the substrate.

7. The energy delivery device of claim 1 further comprising:

a treatment tip having a housing,

wherein the applicator is arranged inside the housing.

8. The energy delivery device of claim 7 further comprising:

a handpiece,

wherein the treatment tip is configured to be releasably attached to the handpiece.

9. The energy delivery device of claim 1 wherein the ceramic material has a thermal conductivity that is greater than a thermal conductivity of polyimide.

10. The energy delivery device of claim 1 wherein the ceramic material has a thermal conductivity that is greater than 20 watts per meter-Kelvin.

11. The energy delivery device of claim 1 wherein the ceramic material has a dielectric loss tangent that is less than 1×10 −4 in a frequency range from 1 Megahertz to 20 Megahertz.

12. The energy delivery device of claim 1 wherein the thickness of the substrate is rotationally symmetric about the centerline.

13. A method of delivering high-frequency energy, the method comprising:

transferring the high-frequency energy from an electrode through a substrate to treat tissue proximate to the electrode with a current density that is smaller near one or more outer edges of the electrode than inward from the one or more outer edges of the electrode,

wherein the substrate has a thickness that varies as a function of position relative to one or more outer edges of the substrate, the substrate has a centerline, the substrate comprises a ceramic material, the ceramic material is aluminum oxide having a dielectric constant of about 10 in a frequency range from 1 Megahertz to 20 Megahertz or aluminum nitride having a dielectric constant of about 9 in a frequency range from 1 Megahertz to 20 Megahertz, the ceramic material of the substrate extends from the centerline to the one or more outer edges of the substrate, and the thickness of the ceramic material of the substrate increases non-linearly with increasing distance from the centerline.

14. An energy delivery device comprising:

an applicator including an electrode and a substrate comprising a ceramic material, the substrate having a first surface, a second surface opposite to the first surface, and one or more outer edges between the first surface and the second surface, and the substrate having a thickness between the first surface and the second surface that varies as a function of position relative to the one or more outer edges,

wherein the ceramic material is aluminum oxide having a dielectric constant of about 10 in a frequency range from 1 Megahertz to 20 Megahertz, the substrate has a centerline, the ceramic material of the substrate extends from the centerline to the one or more outer edges, and the thickness of the ceramic material of the substrate increases non-linearly with increasing distance from the centerline.

15. The energy delivery device of claim 14 wherein the first surface of the substrate has a concave shape with a radius of curvature.

16. The energy delivery device of claim 15 wherein the second surface of the substrate is planar.

17. The energy delivery device of claim 16 wherein the electrode is arranged on the second surface of the substrate.

18. The energy delivery device of claim 15 wherein the electrode is arranged on the first surface of the substrate.

19. The energy delivery device of claim 14 wherein the ceramic material has a thermal conductivity that is greater than 20 watts per meter-Kelvin.

20. The energy delivery device of claim 14 wherein the ceramic material has a dielectric loss tangent that is less than 1×10 −4 in a frequency range from 1 Megahertz to 20 Megahertz.

21. The energy delivery device of claim 14 wherein the electrode is centered about the centerline of the substrate.

22. The energy delivery device of claim 14 further comprising:

a treatment tip having a housing,

wherein the applicator is arranged inside the housing.

23. The energy delivery device of claim 22 further comprising:

a handpiece,

wherein the treatment tip is configured to be releasably attached to the handpiece.

24. The energy delivery device of claim 14 wherein the thickness of the substrate is rotationally symmetric about the centerline.

Assignments (11)
U.S. PATENT SECURITY AGREEMENT Recorded Nov 25, 2025
From: SOLTA MEDICAL IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0394 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
CONFIRMATORY PATENTS ASSIGNMENT Recorded Jan 11, 2023
From: BAUSCH HEALTH IRELAND LIMITED
To: SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 062352/0396 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY INTEREST Recorded Mar 30, 2022
From: BAUSCH+LOMB IRELAND LIMITED; BAUSCH HEALTH IRELAND LIMITED; BAUSCH & LOMB INCORPORATED; SALIX PHARMACEUTICALS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 059446/0670 →
SECURITY INTEREST Recorded Mar 30, 2022
From: BAUSCH+LOMB IRELAND LIMITED; BAUSCH HEALTH IRELAND LIMITED; BAUSCH & LOMB INCORPORATED; SALIX PHARMACEUTICALS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 059446/0722 →
Continuity (2)
Provisional Application 62777540 · Dec 10, 2018
Related Publication 20220022937A1 · Jan 27, 2022
References Cited (46)
US 4232676A · Herczog · 1980 [cited by examiner]
US 5324289A · Eggers · 1994 [cited by examiner]
US 6413255B1 · Stern · 2002 [cited by applicant]
US 6855145B2 · Ciarrocca · 2005 [cited by examiner]
US 7033354B2 · Keppel · 2006 [cited by examiner]
US 7115123B2 · Knowlton et al. · 2006 [cited by applicant]
US 7452358B2 · Stern et al. · 2008 [cited by applicant]
US 8685017B2 · Stern et al. · 2014 [cited by applicant]
US 8702691B2 · Weber et al. · 2014 [cited by applicant]
US 11504182B2 · Woloszko · 2022 [cited by examiner]
US 20020052600A1 · Davison · 2002 [cited by examiner]
US 20040186535A1 · Knowlton · 2004 [cited by applicant]
US 20070088413A1 · Weber et al. · 2007 [cited by applicant]
US 20080027428A1 · Palanker et al. · 2008 [cited by applicant]
US 20100179531A1 · Nebrigic et al. · 2010 [cited by applicant]
US 20150201993A1 · Schomacker · 2015 [cited by examiner]
CN 101351162A · 2009 [cited by applicant]
JP 533737U · 1993 [cited by applicant]
JP 2002537939A · 2002 [cited by applicant]
JP 2005512671A · 2005 [cited by applicant]
JP 2006521889A · 2006 [cited by applicant]
JP 2009254651A · 2009 [cited by applicant]
JP 2012196340A · 2012 [cited by applicant]
KR 1020050114676A · 2005 [cited by applicant]
WO 200053112A1 · 2000 [cited by applicant]
WO 2003053266A2 · 2003 [cited by applicant]
WO 2004090939A2 · 2004 [cited by applicant]
WO 2018146729A1 · 2018 [cited by applicant]
The International Bureau of WIPO, International Preliminary Report on Patentability issued Jun. 8, 2021 in International Application No. PCT/EP2019/083788. [cited by applicant]
Taiwan Intellectual Property Office, Examination Report issued in Taiwanese Patent Application Serial No. 108144514 on Jan. 5, 2023, 16 pages. [cited by applicant]
European Patent Office, International Search Report and Written Opinion issued Mar. 24, 2020 in PCT/EP2019/083788. [cited by applicant]
China National Intellectual Property Administration, First Office Action and Search Report issued in Patent Application Serial No. 201980081238.2 on Dec. 27, 2023; 7 pages. [cited by applicant]
Taiwan Intellectual Property Office; Notice of Allowance issued in Taiwanese Patent Application Serial No. 108144514 on Aug. 7, 2023; 3 pages. [cited by applicant]
Japanese Patent Office, Notice of Reasons for Rejection issued in Patent Application Serial No. 2021-531990 on Sep. 8, 2023; 10 pages. [cited by applicant]
Japanese Patent Office, Notice of Reasons for Rejection issued in Patent Application Serial No. 2021-531990 on Feb. 28, 2024; 12 pages. [cited by applicant]
European Patent Office, Communication pursuant to Article 94(3) EPC issued in European patent application No. 19817631.5 on May 13, 2024; 4 pages. [cited by applicant]
Australian Intellectual Property Office, Examination Report No. 1 issued in Australian Patent Application No. 2019400030 on Jun. 13, 2024; 3 pages. [cited by applicant]
Mexican Intellectual Property Office, First Office Action issued in Mexican Patent Application No. MX/a/2021/006845 on Jun. 21, 2024; 10 pages. [cited by applicant]
Chinese Intellectual Property Office, Second Office Action issued in Chinese Patent Application No. 201980081238.2 on Jun. 22, 2024; 15 pages. [cited by applicant]
Australian Intellectual Property Office, Notice of Acceptance for Patent Application issued in Australian Patent Application No. 2019400030 on Sep. 2, 2024; 3 pages. [cited by applicant]
English translation of Japanese Patent Application No. 2021-531990, published as JP5-33737U on May 7, 1993; 9 pages. [cited by applicant]
Mexican Intellectual Property Office, Second Office Action issued in Mexican Patent Application No. MX/a/2021/006845 on Sep. 5, 2024; 12 pages. [cited by applicant]
Korean Intellectual Property Office, Notice of Preliminary Rejection issued in Korean Patent Application No. 10-2021-7017382 on Oct. 21, 2024; 11 pages. [cited by applicant]
Japanese Patent Office, Final Office Action issued in Japanese Patent Application No. 2021-531990 on Nov. 1, 2024; 8 pages. [cited by applicant]
Hashimoto, Kaoru, “Materials for Ceramic Substrates/Boards,” Purinto Kairo Gijutsu Binran; Printed Circuit Technology Handbook; Third Edition, May 30, 2006; pp. 1018-1034. [cited by applicant]
China National Intellectual Property Administration, Rejection Decision and Search Report issued in Chinese Patent Application No. 201980081238.2 on Jan. 21, 2025; 24 pages. [cited by applicant]